The purpose of this study is to determine whether patients treated for chronic hepatitis C
(HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger
immune response compared to patients treated after kidney transplant. 25 patients with
chronic kidney disease (CKD) and HCV will be treated with zepatier and 25 kidney transplant
recipients with chronic kidney disease will be treated with zepatier. Blood markers of immune
function will be monitored in both groups to determine their response to therapy.